• 1. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 2. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 3. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502
• 4. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 5. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389

Introduction to Ribavirin Carboxylic Acid (CAS No. 39925-19-4)

Ribavirin Carboxylic Acid, with the chemical identifier CAS No. 39925-19-4, is a compound of significant interest in the field of pharmaceutical chemistry and medicinal biology. This compound belongs to the nucleoside analog class, a category renowned for its broad-spectrum antiviral properties. The carboxylic acid derivative of Ribavirin represents a modified version of the well-known antiviral agent Ribavirin, which has been widely used in the treatment of viral infections, particularly in combination therapies for chronic hepatitis C and other RNA virus infections.

The synthesis and application of Ribavirin Carboxylic Acid have garnered attention due to its potential advantages over the parent compound. The introduction of a carboxylic acid group into the molecular structure not only modifies its pharmacokinetic properties but also opens up new avenues for drug design and development. This modification can enhance binding affinity to viral polymerases, improve metabolic stability, or facilitate further derivatization for enhanced therapeutic efficacy.

In recent years, there has been a surge in research focused on developing novel antiviral agents capable of combating emerging viral threats. Ribavirin Carboxylic Acid has emerged as a promising candidate in this context. Its unique chemical structure allows it to interfere with viral replication at multiple stages, making it a versatile tool in antiviral drug discovery. The compound's ability to inhibit RNA-dependent RNA polymerase activity is particularly noteworthy, as it directly targets the machinery responsible for viral genome replication.

One of the most compelling aspects of Ribavirin Carboxylic Acid is its potential for combination therapy. The synergistic effects observed when used in conjunction with other antiviral agents have been documented in several preclinical studies. For instance, its administration alongside nucleoside reverse transcriptase inhibitors (NRTIs) has shown enhanced efficacy against certain RNA viruses. This synergy is attributed to the distinct mechanisms of action, which collectively disrupt viral replication more effectively than monotherapy.

The pharmacological profile of Ribavirin Carboxylic Acid has been extensively studied in vitro and in vivo. Initial pharmacokinetic analyses indicate that this compound exhibits favorable absorption, distribution, metabolism, and excretion (ADME) properties. Unlike its parent compound, Ribavirin Carboxylic Acid demonstrates improved bioavailability and prolonged half-life, which could translate into less frequent dosing requirements for patients. Additionally, preliminary toxicological studies suggest that it may exhibit a reduced toxicity profile compared to Ribavirin, making it a potentially safer alternative for long-term treatment regimens.

Advances in computational chemistry and molecular modeling have further accelerated the development of Ribavirin Carboxylic Acid as an antiviral agent. These techniques have enabled researchers to predict binding interactions with viral targets with high precision, facilitating the design of more effective derivatives. For example, structure-activity relationship (SAR) studies have identified key structural features that enhance potency while minimizing off-target effects. Such insights are crucial for optimizing drug candidates before they enter clinical trials.

The clinical potential of Ribavirin Carboxylic Acid has not gone unnoticed by regulatory agencies worldwide. Several Investigational New Drug (IND) applications have been submitted based on preclinical data demonstrating its efficacy against various RNA viruses. While large-scale clinical trials are still underway, preliminary results are promising and suggest that this compound could fill unmet medical needs in areas where existing treatments are limited or ineffective.

Emerging research also highlights the potential application of Ribavirin Carboxylic Acid beyond traditional antiviral therapies. Its ability to modulate immune responses has raised interest in exploring its use as an immunomodulatory agent. Studies indicate that this compound may enhance host immune responses against viral infections by activating specific immune pathways. This dual mechanism of action—directly inhibiting viral replication while bolstering the host immune system—could provide a significant therapeutic advantage.

The development of novel delivery systems for Ribavirin Carboxylic Acid is another area of active research. Nanotechnology-based formulations have shown promise in improving drug delivery efficiency and bioavailability. For instance, liposomes and polymeric nanoparticles have been investigated as carriers for this compound, with the aim of achieving targeted release and sustained drug delivery profiles. Such innovations could enhance therapeutic outcomes while reducing side effects associated with high systemic concentrations.

Environmental considerations also play a role in the broader adoption of Ribavirin Carboxylic Acid as a therapeutic agent. Sustainable synthesis methods are being explored to minimize environmental impact without compromising efficacy or safety. Green chemistry principles are being applied to optimize synthetic routes, reduce waste generation, and improve energy efficiency during production processes. These efforts align with global initiatives to promote sustainable pharmaceutical manufacturing practices.

The future prospects for Ribavirin Carboxylic Acid appear bright, with ongoing research uncovering new applications and refining existing ones. Collaborative efforts between academic institutions, pharmaceutical companies, and regulatory bodies are essential to translate laboratory findings into clinical reality efficiently. As our understanding of viral pathogenesis continues to evolve, compounds like Ribavirin Carboxylic Acid will remain at the forefront of antiviral drug development—a testament to their versatility and therapeutic potential.

• 40372-03-0(Ribavirin 2,3,5-Tri-O-acetyl)
• 38934-69-9(1-b-D-Ribofuranosyl-1,2,4-triazole-3-carboxylic Acid Methyl Ester(Ribavirin Impurity H))
• 131922-29-7(1H-1,2,4-Triazole-3-carboxamide,1-(2,3-anhydro-b-D-ribofuranosyl)-)
• 101843-94-1(1H-1,2,4-Triazole-3-carboxamide,1-(2,3,5-tri-O-butyl-b-D-ribofuranosyl)-)
• 57198-02-4(a-Ribavirin (Ribavirin Impurity B))
• 66510-90-5(1-[(2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide)
• 39925-10-5(1-(2,3,5-Tri-O-acetyl-b-D-ribofuranosyl)-1,2,4-triazole-3-carboxylic Acid Methyl Ester)
• 36791-04-5(Ribavirin)
• 206269-27-4(Levovirin)
• 40372-06-3(2'-Deoxyribavirin)